Mark Haden
Corporate Officer/Principal presso CLEARMIND MEDICINE INC.
Patrimonio netto: 160 $ in data 30/04/2024
Profilo
Mark Haden is currently the Vice President of Business Development at Clearmind Medicine, Inc. He previously worked as the Director of Clinical Trials at Psygen Labs, Inc. from 2021 to 2022 and as the Executive Director at Multidisciplinary Association for Psychedelic Studies Canada from 2017 to 2021.
Haden received his undergraduate and graduate degrees from the University of British Columbia.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CLEARMIND MEDICINE INC.
0.00% | 31/10/2023 | 133 ( 0.00% ) | 160 $ | 30/04/2024 |
Posizioni attive di Mark Haden
| Società | Posizione | Inizio |
|---|---|---|
| CLEARMIND MEDICINE INC. | Corporate Officer/Principal | 01/07/2021 |
Precedenti posizioni note di Mark Haden
| Società | Posizione | Fine |
|---|---|---|
Psygen Labs, Inc.
 Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Corporate Officer/Principal | 01/03/2022 |
Formazione di Mark Haden
| University of British Columbia | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CLEARMIND MEDICINE INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Psygen Labs, Inc.
Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Health Technology |
- Borsa valori
- Insiders
- Mark Haden
